EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

Huayi Li iD, Minghua Xiang iD, Qiuyang Xu iD, Jiahao Liu, Xiaofei Jiao, Wei Mu, Xiaoying Lv, Kangjia Tao, Yu Xu, Dongchen Zhou, Wenjian Gong, Danmei Yan und 9 weitere

Advanced Science · 2026

DOI: 10.1002/advs.76994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Huayi Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Hu…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Quinolines, Poly(ADP-ribose) Polymerase Inhibitors, Indoles. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Key Technology Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)‐T cell therapy is largely ineffective in most solid tumors, partially because of inadequate intratumoral trafficking. Bridging therapy, administered between leukapheresis and CAR‐T cell infusion, offers a distinct opportunity to control the disease and precondition the tumor microenvironment without directly exposing CAR‐T cells to concomitant drugs. Here, a poly (ADP‐ribose) polymerase (PARP) inhibitor combined with anlotinib is evaluated as bridging therapy for ovarian cancer. In immunocompetent mice bearing ovarian tumors, this regimen induces durable intratumoral T cell accumulation associated with activation of the cGAS‐STING pathway, vascular normalization, and reduced fibrillar collagen deposition. Furthermore, TGFβ‐resistant, dual‐target mesothelin (MSLN)/CD19 CAR‐T cells are engineered using a bait‐and‐switch strategy. Niraparib plus anlotinib administered as bridging therapy before CAR‐T cell infusion enhances CAR‐T cell infiltration and antitumor activity across multiple preclinical ovarian cancer models. These findings inform an ongoing phase I clinical trial (NCT05141253) evaluating the safety of these engineered CAR‐T cells following bridging therapy in patients with refractory MSLN‐positive solid tumors. Collectively, our findings support a clinically actionable bridging therapy with translational potential for potentiating CAR‐T cell therapy in ovarian cancer and highlight bridging therapy as a translational approach to improve CAR‐T cell access and efficacy in solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsQuinolinesPoly(ADP-ribose) Polymerase InhibitorsIndolesImmunotherapy, AdoptiveReceptors, Chimeric AntigenFemaleAnimalsHumansMiceTumor Microenvironment

Stichwörter der Autor:innen

CAR‐T cell therapyPARP inhibitoranlotinibbridging therapyovarian cancer

Substanzen

QuinolinesPoly(ADP-ribose) Polymerase InhibitorsIndolesanlotinibReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wu…
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Huayi Li, Minghua Xiang, Qiuyang Xu, Yixin Hu, Jundong Li, Guang Hu, Li Zhu, Yong Fang

Förderung

  • National Natural Science Foundation of China
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Key Technology Research and Development Program of China
  • Innovation Group Project of Hubei Province
  • Postdoctoral Fellowship Program and China Postdoctoral Science Foundation
  • Guangdong Basic and Applied Basic Research Foundation
  • Chih Kuang Scholarship for Outstanding Young Physician-Scientists of Sun Yat-sen University Cancer Center
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Li, H., Xiang, M., Xu, Q., Liu, J., Jiao, X., Mu, W., Lv, X., Tao, K., Xu, Y., Zhou, D., Gong, W., Yan, D., Hu, Y., Xu, S., Zhao, B., Li, J., Gai, Y., Hu, G., Zhu, L., …, & Fang, Y. (2026). PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy. Advanced Science. https://doi.org/10.1002/advs.76994

Vancouver

Li H, Xiang M, Xu Q, Liu J, Jiao X, Mu W, et al. PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy. Advanced Science. 2026. doi:10.1002/advs.76994

BibTeX
@article{Li2026,
  author = {Li, Huayi and Xiang, Minghua and Xu, Qiuyang and Liu, Jiahao and Jiao, Xiaofei and Mu, Wei and Lv, Xiaoying and Tao, Kangjia and Xu, Yu and Zhou, Dongchen and Gong, Wenjian and Yan, Danmei and Hu, Yixin and Xu, Sen and Zhao, Bingbing and Li, Jundong and Gai, Yongkang and Hu, Guang and Zhu, Li and Gao, Qinglei and Fang, Yong},
  title = {PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76994}
}
Kostenlos starten →